Discussion about this post

User's avatar
Britt Stromberg's avatar

I’m so glad you wrote about this as I’ve been wondering what the hell is up with my boobs. They’ve always been large, and while they’re not expanding in cup size (yet), they feel heavier than ever. I also have inflammation in other body parts. I will be talking to my doctor about GLP-1 microdosing. The weight loss would be a bonus as I’ve gained 2 pant sizes since menopause. Otherwise I feel strong and healthy. Thank you, Deb, for personalizing this issue. And what a loving, complicated family history!

Ariel Parrish's avatar

Accessibility and insurance coverage of GLP-1 medications could be a topic for a whole book. Insurance companies are rapidly dropping coverage even for patients who truly meet the diagnostic criteria, people who could massively benefit from these life-changing drugs. They are just too expensive.

The brand-name versions cost $500-1000+/month, slightly less for the lowest starting doses. The meds became available via compounding pharmacies and telehealth prescribers during temporary shortages for <$200/month. Right now you can still get compounded semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), but Novo Nordisk and Eli Lilly are charging hard to shut that down. Lilly is worth almost a trillion dollars at this point.

True “microdosing” (using less than the lowest commercially available dose) is really only possible with compounded meds, which come in multi-use vials that allow you to control your dose. There are ways around using the full dose from a pre-dosed autoinjector or single-use vial, but those methods are not a mainstream solution.

And then there’s the gray market, with cheap “research-only”/"not for human use" drugs coming in from China. Humans are absolutely using them.

Don’t get me started on how problematic VC-funded telehealth is becoming. And med spas with often shady prescribing and dispensing practices. And the grifty menopause/wellness space in general. All absolutely exploiting women, but also meeting a need in the marketplace that mainstream medicine and insurance companies are not satisfying. Does this comment box have a character limit? Lol.

The bright point in all this is that the GLP-1 drug-discovery pipeline is huge and moving fast, with dozens of new meds currently in the works. As new drugs hit the market, we can *hope* that the older ones will become more affordable and accessible. And that as you mentioned, they will be approved for more indications beyond the current ones (diabetes, obesity, obstructive sleep apnea, cardiovascular risk, and MASH so far I believe), and - fingers crossed - eventually covered by insurance.

14 more comments...

No posts

Ready for more?